Littérature scientifique sur le sujet « Seconde neoplasie »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Seconde neoplasie ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Seconde neoplasie"
Cantley, Richard L. « Fine-Needle Aspiration Cytology of Cellular Basaloid Neoplasms of the Salivary Gland ». Archives of Pathology & ; Laboratory Medicine 143, no 11 (11 septembre 2019) : 1338–45. http://dx.doi.org/10.5858/arpa.2019-0327-ra.
Texte intégralBaum, Berit. « Not Just Uterine Adenocarcinoma—Neoplastic and Non-Neoplastic Masses in Domestic Pet Rabbits (Oryctolagus cuniculus) : A Review ». Veterinary Pathology 58, no 5 (20 avril 2021) : 890–900. http://dx.doi.org/10.1177/03009858211002190.
Texte intégralde Moura, Joel Pereira, Sérgio Mancini Nicolau, João Norberto Stávale, Maria Aparecida da Silva Pinhal, Leandro Luongo de Matos, Edmund Chada Baracat et Geraldo Rodrigues de Lima. « Heparanase-2 Expression in Normal Ovarian Epithelium and in Benign and Malignant Ovarian Tumors ». International Journal of Gynecologic Cancer 19, no 9 (novembre 2009) : 1494–500. http://dx.doi.org/10.1111/igc.0b013e3181a834a2.
Texte intégralLesnic, Evelina, et Alina Malic. « Particularities of the evolution of the patients with tuberculosis associated with the pulmonary neoplastic process ». Public Health, Economy and Management in Medicine, no 2(89) (août 2021) : 45–50. http://dx.doi.org/10.52556/2587-3873.2021.2(89).08.
Texte intégralFatima, Rasheed, Sandhya M. et Sowmya T. S. « Study of histomorphological pattern of ovarian neoplastic and non-neoplastic lesions ». International Journal of Research in Medical Sciences 5, no 5 (26 avril 2017) : 2095. http://dx.doi.org/10.18203/2320-6012.ijrms20171849.
Texte intégralGonzález, Iván A., Douglas R. Stewart, Kris Ann P. Schultz, Amanda P. Field, D. Ashley Hill et Louis P. Dehner. « DICER1 tumor predisposition syndrome : an evolving story initiated with the pleuropulmonary blastoma ». Modern Pathology 35, no 1 (1 octobre 2021) : 4–22. http://dx.doi.org/10.1038/s41379-021-00905-8.
Texte intégralCharak, Annu, Irfan Ahmed, Bushra Rashid Sahaf, Rehana Qadir et A. R. Rather. « Clinico-pathological spectrum of testicular and paratesticular lesions : a retrospective study ». International Journal of Research in Medical Sciences 6, no 9 (25 août 2018) : 3120. http://dx.doi.org/10.18203/2320-6012.ijrms20183656.
Texte intégralEscobar, P. F., R. Patrick, L. Rybicki, N. Al-Husaini, C. M. Michener et J. P. Crowe. « Primary gynecological neoplasms and clinical outcomes in patients diagnosed with breast carcinoma ». International Journal of Gynecologic Cancer 16, Suppl 1 (janvier 2006) : 118–22. http://dx.doi.org/10.1136/ijgc-00009577-200602001-00019.
Texte intégralBokemeyer, C., et H. J. Schmoll. « Secondary neoplasms following treatment of malignant germ cell tumors. » Journal of Clinical Oncology 11, no 9 (septembre 1993) : 1703–9. http://dx.doi.org/10.1200/jco.1993.11.9.1703.
Texte intégralTorres, L. N., J. M. Matera, C. H. Vasconcellos, J. L. Avanzo, F. J. Hernandez-Blazquez et M. L. Z. Dagli. « Expression of Connexins 26 and 43 in Canine Hyperplastic and Neoplastic Mammary Glands ». Veterinary Pathology 42, no 5 (septembre 2005) : 633–41. http://dx.doi.org/10.1354/vp.42-5-633.
Texte intégralThèses sur le sujet "Seconde neoplasie"
Ricci, Marcos Desiderio. « Impacto da mamoplastia redutora contralateral, em pacientes com câncer de mama, na detecção de carcinoma oculto sincrônico e diminuição no risco de carcinoma metacrônico ». Universidade de São Paulo, 2005. http://www.teses.usp.br/teses/disponiveis/5/5139/tde-20092010-180741/.
Texte intégralINTRODUCTION: The principal risk factor for breast cancer is a personal antecedent of contralateral breast cancer. A reduction mammoplasty has an esthetical purpose and implies in the reduction of the risk of breast cancer. The contralateral and reduction mammoplasty with simetrization in patients with cancer and submitted to surgeries, contributes for the diagnosis of precursor lesions and occult carcinoma. OBJECTIVES: Determine the occurrence of precursor lesions and breast occult carcinoma in patients submitted to reduction mammoplasty with simetrization. Compare these patients with a control group of patients that were not submitted to that type of surgery, analyzing the time of initiating of the adjuvant therapy (chemotherapy and radiotherapy), disease-free time and total survival, occurrence tax and factors related with metachronic cancer. METHODS: 249 women with diagnosis of non-metastatic invasive breast carcinoma were studied and divided in two groups. The studied group was constituted of 114 women, who were submitted to reduction and contralateral mammoplasty, and the control group constituted of 135 patients, who were not submitted to this type of surgery. All the patients suspected to have lesions on the contralateral breast were excluded from this study, as well as, those with antecedents of reduction mammoplasty. RESULTS: The patients submitted to reduction mammoplasty with simetrization had a diagnosis of an occult, synchronic and invasive carcinoma in 1.8% of the cases, ductal carcinoma in situ in 2.6%, and proliferative and atypical lesions were found in 14.9%. The time of initiating the adjuvant therapy had no influence with the mammoplasty of simetrization (p=0.826). Patients submitted to mammoplasty, metachronic contralateral cancer occurred in 1.8% of the cases, whereas the control group demonstrated in 6.7% evidencing association between contralateral and reduction mammoplasty of occurrence of metachronic cancer (p=0.094). The disease-free time of the disease and total survival was not influenced by the mammoplasty. The factors related with a greater occurrence were the familiar antecedents and the diagnosis of the contralateral tumor in initial stage. The adjuvant chemotherapy adjuvant was related with the reduction of the occurrence. CONCLUSIONS: The contralateral and reduction mammoplasty with simetrization gives an opportunity for diagnosis of risk lesions, in situ and invasive tumors, besides demonstrating evidences of reduction of metachronic cancer during the oncological follow-up.
Prochazka, Michaela. « The risk of second primary lung carcinoma in breast cancer patients / ». Stockholm, 2006. http://diss.kib.ki.se/2006/91-7140-649-2/.
Texte intégralPinto, Jorge Luiz Freire. « DNA plasmático e urinário em pacientes com câncer de mama - possibilidade de um novo marcador de instabilidade genética tumoral induzida por quimioterapia ». Universidade de São Paulo, 2009. http://www.teses.usp.br/teses/disponiveis/5/5167/tde-05032010-115349/.
Texte intégralBreast cancer has the major mortality in women among all kind of cancer. The use of alkylating agents at the treatment of this disease is associated with genomic instability. This instability could be associated with the development of secondary cancer, for example, leukemia. The present thesis evaluated microsatellite instability in blood, pellet cells urinary and plasma in patients with breast cancer at diagnosis, 3 and 6 months after the beginning of chemotherapy. There were evaluated also Free Plasmatic DNA concentration as a possible tumoral marker with the serum markers CEA and CA15.3 used in breast cancer follow up. The microsatellites regions assayed were: Tp53-ALU,Tp53.PCR15.1, BAT 40, BAT26, FMR2 e APC. Among the 40 patients included at the present study 88,57% showed microsallite instability in peripheral mononuclear blood cells, 85,8% in urinary pellet cells samples and 62,5% in Free Plasmatic DNA. There werent statistical significant relationship for the instability found at the three kind of samples assayed. The Free Plasmatic DNA concentration of the patients when compared with healthy donors, showed a statistical significant relationship (p<0,0001). And among patients in neoadjuvant chemotherapy regime who reacted positively by treatment (p=0,02). And there werent statistical significant relationship between Free Plasmatic DNA and serum markers CEA and CA15.3.
Kleinerman, Ruth. « Second cancers following treatment for retinoblastoma ». Thesis, City, University of London, 2016. http://openaccess.city.ac.uk/17330/.
Texte intégralWilson, Carmen Louise Children's Cancer Institute Australia for Medical Research UNSW. « The late effects of therapy in an Australian cohort of childhood cancer survivors ». Awarded By:University of New South Wales. Children's Cancer Institute Australia for Medical Research, 2008. http://handle.unsw.edu.au/1959.4/43794.
Texte intégralBongiovanni, Alberto <1981>. « Predictive And Prognostic Role Of Biological Markers In Neuroendocrine Neoplasia And Evaluation Of Activity And Safety Of Second Line Treatments In Neuroendocrine Carcinoma Patients ». Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2022. http://amsdottorato.unibo.it/9994/1/text%20PHD%20post%20rev_merged.pdf.
Texte intégralHartman, Mikael. « Risk and prognosis of breast cancer among women at high risk of the disease / ». Stockholm : Karolinska institutet, 2007. http://diss.kib.ki.se/2007/978-91-7357-303-0/.
Texte intégralTanizawa, Roberta Sandra da Silva. « Estudo morfológico e por citogenética da medula óssea de portadores de síndrome mielodisplásica secundária no Serviço de Hematologia do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo ». Universidade de São Paulo, 2010. http://www.teses.usp.br/teses/disponiveis/5/5167/tde-27092010-145739/.
Texte intégralMyelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders, characterized by cytopenias, dysplastic bone marrow (BM) and propensity to progress to acute myeloid leukemia. Secondary MDS are associated with risk factors such as congenital disorders (Fanconis anemia), acquired bone marrow failures, exposure to chemotherapy (alkylating agents, topoisomerase II inhibitors) agents and radiation and chemicals (benzene, petroleum). Immunosuppressive agents associated with hematopoietic growth factors are also associated with secondary MDS. The WHO classification has recently adopted the term therapy-related myeloid neoplasms for cases of myeloid malignancies that fulfill morphological criteria not only for MDS but also for AML or myeloproliferative neoplasms.The aim of the study was to analyze clinical, morphological and cytogenetic features of 42 patients with secondary MDS/MN in a cohort of patients diagnosed at our institution from 1987 to 2008. 23 patients (54.8%) were male, median age 53.5 (4-88) years. 45.2% had primary hematologic malignancies, 26.2% aplastic anemia, 14.3% solid tumors and 14.3% other diseases (autoimmune diseases and solid organ transplantation). 33% had undergone chemotherapy alone, 2% RT alone, 26% both modalities and 28% immunosuppressive agents. Five (11.9%) patients had undergone autologous HSCT for treatment of previous malignancies. The median latency between the primary disease and secondary MDS/MN was 85 (23-221) months. Eight patients underwent allogeneic HSCT (allo- HSCT) for treatment of related secondary MDS. Anemia, neutropenia, thrombocytopenia and peripheral blasts were observed in 64.3%, 54.8%, 78.6% and 26.2%, respectively. BM aspirates was poorly representative in 1/3 of cases, 29.7% global hypocellularity, 62.2% more than 5% of blast counts and 14.3% more than 15% of ring sideroblasts. Dysplasia in erythroid, granulocytic and megakaryocytic series was observed in 79.4%, 77.1% and 68.2%, respectively. Twenty two BM biopsies were performed. Global hypocellularity, ALIP and lymphoid nodules were shown in 9.1%, 23.8% and 40.9%. The immunohistochemistry showed more than 1% of CD34+ and CD117+ cells, clusters of CD34+ and CD117+ and immunoexpression of p53 protein in 77.2%, 82.3%, 59%, 29.4% and 33.3%, respectively. Clonal abnormalities were observed in 84.3% of cases with high prevalence of unbalanced (96%) rearrangements. 37% showed monosomy 7 and 44.4% complex karyotypes. The median overall survival was 5.7 for all patients and 40 months for patients treated with allo-HSCT (P=0.007). Hematologic malignancies, low platelet count, serum high LDH and ferritin, detection of CD117+ clusters, positive immunoexpression of p53, abnormal cytogenetics, intermediate-II or high-risk IPSS groups were associated with poor survival. No parameter studied from bone marrow aspirate had impact in survival. p53 expression was associated to abnormal karyotype (P=0.092) and IPSS risk (P=0.054). There was no association between the presence of ALIP, BM blast counts and immunoexpression of CD34+ and CD117+. Our study shows that cytogenetic analysis and BM immunohistochemistry are very important in diagnosis and prognosis, and that allo-HSCT could improve the survival of secondary MDS/MN. More studies with larger numbers of cases should be conducted to confirm the importance of the IPSS for secondary MDS, probably replacing the bone marrow aspirate blast counts by the immunohistochemistry detection of precursor cells
Birgisson, Helgi. « Cancer of the Colon and Rectum : Population Based Survival Analysis and Study on Adverse Effects of Radiation Therapy for Rectal Cancer ». Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2006. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-6824.
Texte intégralPereira, Lucy. « Validation of the 60-second chair rise as a measure of physical function in patients with non-small cell lung cancer ». Thesis, McGill University, 2008. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=116113.
Texte intégralSubjects completed the chair rise test, 6MWT, hand grip, and the SF-36 pre and post chemotherapy. Evidence for construct and discriminant validity but not predictive validity was provided for the chair rise test. The 60-second chair rise may be too strenuous for persons with severe disability but a standardized timed-based chair rise test is needed.
Livres sur le sujet "Seconde neoplasie"
T, Galeotti, dir. Cell membranes and cancer : Proceedings of the Second International Workshop on Membranes in Tumour Growth, Rome, Italy, June 17-20, 1985. Amsterdam : Elsevier Science, 1985.
Trouver le texte intégralPeter, De Wulf, et Earnshaw William C, dir. The kinetochore : From molecular discoveries to cancer therapy. New York : Springer, 2009.
Trouver le texte intégralPeter, De Wulf, et Earnshaw William C, dir. The kinetochore : From molecular discoveries to cancer therapy. New York : Springer, 2009.
Trouver le texte intégralK, Cavenee W., Ponder, B. A. J. 1944-, Solomon E et Imperial Cancer Research Fund (Great Britain), dir. Genetics and cancer : A second look. Plainview, N.Y : Cold Spring Harbor Laboratory Press, 1995.
Trouver le texte intégralS, Mitchell Malcolm, dir. Immunity to cancer II : Proceedings of the Second Conference on Immunity to Cancer held at Williamburg, Virginia, November 9-11, 1987. New York : Liss, 1989.
Trouver le texte intégralJulian, Rosenthal C., et Rotman Marvin 1933-, dir. Infusion chemotherapy--irradiation interactions : Principles and applications to organ salvage and prevention of second primary neoplasms. New York : Elsevier, 1998.
Trouver le texte intégralMcLean, David I., MD, FRCPC. et Williams Dan 1957-, dir. The prevention of second primary cancers : A resource for clinicians and health managers. Basel : Karger, 2008.
Trouver le texte intégralSecond primary cancers and cardiovascular disease after radiation therapy. Bethesda, Md : National Council on Radiation Protection and Measurements, 2011.
Trouver le texte intégral1944-, Foley Kathleen M., Bonica John J. 1917- et Ventafridda Vittorio, dir. Proceedings of the Second International Congress on Cancer Pain. New York : Raven Press, 1990.
Trouver le texte intégralInstitute of Medicine (U.S.). Planning Committee on Policy Issues in Nanotechnology and Oncology et National Cancer Policy Forum (U.S.), dir. Nanotechnology and oncology : Workshop summary. Washington,D.C : National Academies Press, 2011.
Trouver le texte intégralChapitres de livres sur le sujet "Seconde neoplasie"
Bhatia, Smita. « Second Malignant Neoplasms ». Dans Handbook of Long Term Care of The Childhood Cancer Survivor, 209–20. Boston, MA : Springer US, 2015. http://dx.doi.org/10.1007/978-1-4899-7584-3_14.
Texte intégralVannucchi, Alessandro M. « Polycythemia Vera and Essential Thrombocythemia : When to Change Therapy – Second-Line Options ». Dans Myeloproliferative Neoplasms, 119–29. Berlin, Heidelberg : Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-24989-1_11.
Texte intégralRussell, Robert T., et Anna T. Meadows. « Organ Dysfunction, Second Malignant Neoplasms, and Survival ». Dans The Surgery of Childhood Tumors, 615–27. Berlin, Heidelberg : Springer Berlin Heidelberg, 2016. http://dx.doi.org/10.1007/978-3-662-48590-3_32.
Texte intégralPaterson, Felicity, Susannah Stanway, Lone Gothard et Navita Somaiah. « Second Primary Neoplasms Following a Diagnosis of Breast Cancer ». Dans Breast Cancer Survivorship, 213–34. Cham : Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-41858-2_17.
Texte intégralKleinerman, Ruth A., Jasmine H. Francis et David H. Abramson. « Second Primary Neoplasms in Retinoblastoma : Effect of Gene and Environment ». Dans Albert and Jakobiec's Principles and Practice of Ophthalmology, 7941–52. Cham : Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-42634-7_266.
Texte intégralKleinerman, Ruth A., Jasmine H. Francis et David H. Abramson. « Second Primary Neoplasms in Retinoblastoma : Effect of Gene and Environment ». Dans Albert and Jakobiec's Principles and Practice of Ophthalmology, 1–12. Cham : Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-319-90495-5_266-1.
Texte intégralAmsbaugh, Mark J., et Shiao Y. Woo. « Second Neoplasms After Successful Treatment for Pediatric Central Nervous System Tumors ». Dans Radiation Oncology for Pediatric CNS Tumors, 595–624. Cham : Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-55430-3_35.
Texte intégralNosé, Vânia, et E. Tessa Hedley-Whyte. « Diseases of the Pituitary Gland ». Dans Escourolle and Poirier's Manual of Basic Neuropathology, 343–64. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199929054.003.0014.
Texte intégralPlastaras, John P., Daniel M. Green et Giulio J. D'Angio. « Second Malignant Neoplasms ». Dans Abeloff's Clinical Oncology, 1023–37. Elsevier, 2008. http://dx.doi.org/10.1016/b978-0-443-06694-8.50070-1.
Texte intégralFriedman, Debra L. « Second Malignant Neoplasms ». Dans Abeloff's Clinical Oncology, 741–50. Elsevier, 2020. http://dx.doi.org/10.1016/b978-0-323-47674-4.00050-5.
Texte intégralActes de conférences sur le sujet "Seconde neoplasie"
Farias, Nathália dos Santos, Beatriz Silva Silveira, Isabela Mascarenhas de Andrade, Lara Cordeiro Magalhães, Maria Luísa Sousa Weber et Maria Clara Cotrim Pereira. « Mortality Rate of CNS neoplasms in childhood in Brazil ». Dans XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.202.
Texte intégralLamonier, L., F. Bottcher-Luiz, L. Pietro, L. A. L. A. Andrade, A. A. de Thomaz, C. L. Machado et C. L. Cesar. « Second harmonic generation in human ovarian neoplasias ». Dans BiOS, sous la direction de Ammasi Periasamy, Peter T. C. So et Karsten König. SPIE, 2010. http://dx.doi.org/10.1117/12.842576.
Texte intégralRocha, Ariane Silva da, Maria Paula Curado et Gisele Aparecida Fernandes. « THIRD AND FOURTH IPSILATERAL AND CONTRALATERAL PRIMARY BREAST CANCER IN A COHORT OF WOMEN TREATED FROM 2000 TO 2015 AT AC CAMARGO CANCER CENTER ». Dans Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2040.
Texte intégralPâslaru, Ana Maria, Ana Maria Fătu, Alexandru Nechifor, Laura Florentina Rebegea, Diana Bulgaru Iliescu et Anamaria Ciubara. « PSYCHO-ONCOLOGY. CASE PRESENTATION ». Dans The European Conference of Psychiatry and Mental Health "Galatia". Archiv Euromedica, 2023. http://dx.doi.org/10.35630/2022/12/psy.ro.35.
Texte intégralLamiri, Hadir, Hajer Bettaieb, Hadhami Rouiss, Nesrine Souayeh, Meriem Ouederni, Rahma Bouhmida, Amal Chermiti, Hedhili Oueslati et Chaouki Mbarki. « EP402/#1074 Epidemiology of gestational trophoblastic neoplasia in a second level hospital in Tunisia ». Dans IGCS 2022 Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/ijgc-2022-igcs.491.
Texte intégralSherborne, Amy, Philip Davidson, Katharine Yu, Alice Nakamura, Mamunur Rashid et Jean Nakamura. « Abstract A50 : Mutational analysis of a mouse model of second malignant neoplasms ». Dans Abstracts : AACR Special Conference : Advances in Pediatric Cancer Research : From Mechanisms and Models to Treatment and Survivorship ; November 9-12, 2015 ; Fort Lauderdale, Florida. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.pedca15-a50.
Texte intégralVargas, G., T. Shilagard, Ki-Hong Ho et S. McCammon. « Multiphoton autofluorescence microscopy and second harmonic generation microscopy of oral epithelial neoplasms ». Dans 2009 Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE, 2009. http://dx.doi.org/10.1109/iembs.2009.5332783.
Texte intégralMalev, Carlo C. « Abstract IA15 : Measuring evolution in neoplasms ». Dans Abstracts : Second AACR International Conference on Frontiers in Basic Cancer Research--Sep 14-18, 2011 ; San Francisco, CA. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.fbcr11-ia15.
Texte intégralZong, Xuchen, Jason D. Pole, Paul Grundy, Salaheddin M. Mahmud, Louise Parker et Rayjean J. Hung. « Abstract 3713 : Second malignant neoplasms after non-CNS embryonal tumors in North America ». Dans Proceedings : AACR 106th Annual Meeting 2015 ; April 18-22, 2015 ; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-3713.
Texte intégralTran-Thanh, D., D. Tran-Thanh, N. Arneson, M. Pintilie, K. Warren, A. Bane, F. O'Malley, F. O'Malley, S. Done et S. Done. « Amplification of the Prolactin Receptor Gene in Mammary Lobular Neoplasia. » Dans Abstracts : Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 10‐13, 2009 ; San Antonio, TX. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-09-4151.
Texte intégral